The Impact of Peroxiredoxin 3 on Molecular Testing, Diagnosis, and Prognosis in Human Pancreatic Ductal Adenocarcinoma

• Published in: Cancers Vol. 17; no. 13; p. 2212
• Main Authors: Kakehashi, Anna, Suzuki, Shugo, Nishidoi, Yusaku, Hagihara, Atsushi, Ikenaga, Hiroko, Shiota, Masayuki, Qiu, Guiyu, Noura, Ikue, Kuwae, Yuko, Vachiraarunwong, Arpamas, Fujioka, Masaki, Gi, Min, Kawada, Norifumi, Wanibuchi, Hideki
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.07.2025; MDPI
• Subjects: Adenocarcinoma; Age; Biological products; Biomarkers; Blood levels; Cancer; CD44 antigen; Classification; Diagnosis; Enzymes; Ethylenediaminetetraacetic acid; Extracellular vesicles; Females; FOXO3 protein; Growth patterns; Hospitals; Males; Matrix protein; Medical colleges; Medical prognosis; Medical records; Metastases; mRNA; Oxidative stress; Pancreatic cancer; Peroxiredoxin; Prognosis; Protein expression; Proteins; Proteomics; Reactive oxygen species; Reagents; Review boards; RNA; Software; Tumors; California; United States; Massachusetts; Japan; Pennsylvania; Canada; United States > US; peroxiredoxin 3; PDAC; extracellular vesicles; oxidative stress resistance; biomarker; mitochondria

Background/Objective: Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer death and tumors with an extremely poor prognosis. In the present study, novel biomarker candidates useful for the early diagnosis and prognosis of human invasive PDAC were investigated. Methods: Bio...